tradingkey.logo

First Venture Sweden Private Says Sprint Bioscience Sells Cancer Program TREX1 To Gilead Sciences

ReutersNov 24, 2025 3:19 PM

- First Venture Sweden Private AB FIRSTb.ST:

  • SPRINT BIOSCIENCE SELLS CANCER PROGRAM TREX1 TO GILEAD SCIENCES

  • DEAL INCLUDES $14 MILLION UPFRONT AND UP TO $400 MILLION MILESTONES

Further company coverage: [FIRSTb.ST]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI